ClinicalTrials.gg
CompletedNCT06458023Updated May 13, 2026Results posted

TOF Monitoring Using the TetraGraph in Patients Less Than 1 Year of Age

An interventional study of TetraGraph (TM) NMT Monitor in Surgery, sponsored by Joseph D. Tobias. Completed at 1 site in United States. Open to participants aged 1 Month to 12 Months. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Joseph D. Tobias · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
1 Month to 12 Months
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of train-of-four (TOF) monitoring using the TetraGraph Neuromuscular Transmission Monitor in pediatric patients less than 1 year of age.

02

Conditions studied

  • Surgery
03

In context

Lead sponsor

Joseph D. Tobias is the lead sponsor of 28 studies on the registry; 4 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA 1-4
  • ≤ 1 year of age
  • undergoing a surgical procedure with general anesthesia and requiring the administration of an NMBA

Exclusion criteria

Exclusion Criteria:

  • Patients less than 28 days old
  • Patients with history of a peripheral neurologic or neuropathic disorder
  • Patients in whom the upper extremity cannot be used for TOF monitoring
  • Patients undergoing a surgical procedure in which neuromuscular blockade is not required
  • Edematous patients
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    TetraGraph (TM) NMT Monitor

    TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.

    Device: TetraGraph (TM) NMT Monitor

Interventions

  • DeviceTetraGraph (TM) NMT Monitor

    TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.

06

What researchers measure

Primary outcomes

  1. TOFr (%)

    The Train of Four ratio (TOFr) is a quantitative measure used in anesthesia to assess the depth of neuromuscular blockade and recovery, calculated by dividing the amplitude of the fourth twitch by the first twitch after four 2-Hz stimuli. A TOF ratio is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents. A TOF ratio \>/= 90% is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents.

    Time frame: During the surgery (1-3 hrs. avg.)

  2. Amplitude

    The amplitude of the muscle action potential in response to electrical stimulation of its corresponding peripheral nerve.

    Time frame: During the surgery (1-3 hrs. avg.)

Secondary outcomes

  1. Rate of Muscle Recovery

    The amount of time from administration of neuromuscular blockade reversal agent to muscle recovery (TOFr \>/= 90).

    Time frame: Baseline, After reversal of neuromuscular blockade during surgery (avg of 1-3 hrs)

07

Results

Posted May 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneTetraGraph (TM) NMT Monitor
Started50
Completed49
Not completed1
Withdrew: Patient didn't receive neuromuscular blocking agent1

Outcome measures

PrimaryTOFr (%)

The Train of Four ratio (TOFr) is a quantitative measure used in anesthesia to assess the depth of neuromuscular blockade and recovery, calculated by dividing the amplitude of the fourth twitch by the first twitch after four 2-Hz stimuli. A TOF ratio is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents. A TOF ratio \>/= 90% is the standard threshold for safe extubation and indicates sufficient recovery from nondepolarizing agents.

Time frame:
During the surgery (1-3 hrs. avg.)
Reported as:
Mean · percent
TOFr (%)
percentTetraGraph (TM) NMT Monitor
Baseline99 ± 16.3
Recovered (after reversal of neuromuscular blockade)95 ± 10
PrimaryAmplitude

The amplitude of the muscle action potential in response to electrical stimulation of its corresponding peripheral nerve.

Time frame:
During the surgery (1-3 hrs. avg.)
Reported as:
Mean · millivolts
Amplitude
millivoltsTetraGraph (TM) NMT Monitor
Baseline6.8 ± 2.2
Recovered4.7 ± 1.5
SecondaryRate of Muscle Recovery

The amount of time from administration of neuromuscular blockade reversal agent to muscle recovery (TOFr \>/= 90).

Time frame:
Baseline, After reversal of neuromuscular blockade during surgery (avg of 1-3 hrs)
Reported as:
Mean · minutes
Rate of Muscle Recovery
minutesTetraGraph (TM) NMT Monitor
Rate of Muscle Recovery2.7 ± 1.4

Adverse events

Collected over Day of surgery, 1 day. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TetraGraph (TM) NMT Monitor0/49 (0%)0/49 (0%)0/49 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(months)TetraGraph (TM) NMT Monitor
Mean5.45 ± 2.67
Sex: Female, Male
Sex: Female, Male(Participants)TetraGraph (TM) NMT Monitor
Female21
Male28
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TetraGraph (TM) NMT Monitor
Hispanic or Latino4
Not Hispanic or Latino44
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TetraGraph (TM) NMT Monitor
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White34
More than one race10
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)TetraGraph (TM) NMT Monitor
United States49
Weight
Weight(kilograms)TetraGraph (TM) NMT Monitor
Mean3.1 ± 1.83
Participants per weight group
Participants per weight group(Participants)TetraGraph (TM) NMT Monitor
0 to <4 kg3
4 to <6 kg20
6 to <8 kg16
More than 8 kg10
08

Study locations

1 site
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
09

References and documents

Publications

  • Chaney A, Villalobos EE, Rice-Weimer J, Tobias JD. Intraoperative Electromyographic Monitoring in Children Less Than 1 Year of Age. Paediatr Anaesth. 2025 Nov;35(11):934-939. doi: 10.1111/pan.70043. Epub 2025 Aug 27. PubMed 40862479 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Sep 2024, 2 months.

Results were first posted in May 2026, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 13, 2024
StartActual
Jun 11, 2024
Primary completionActual
Sep 4, 2024
CompletionActual
Sep 4, 2024
Results first posted
May 13, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06458023
Lead sponsor
Joseph D. Tobias
Responsible party
Joseph D. Tobias (Chief, Dept. of Anesthesiology & Pain Medicine, Nationwide Children's Hospital) — Sponsor-investigator
First posted
Jun 13, 2024
Start date
Jun 11, 2024
Primary completion
Sep 4, 2024
Completion
Sep 4, 2024
Results posted
May 13, 2026
Last update
May 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion